Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Oct. 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California. 
No comment yet.
Sign up to comment
Scoop.it!
The Chan Zuckerberg Biohub, launched by Facebook CEO Mark Zuckerberg and wife Priscilla Chan, has awarded $50 million to 47 scientists
|
Scoop.it!
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 6, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at BIO CEO & Investor Conference, being held on February 13-14, 2017 at the Waldorf Astoria in New York City.
|
